Bavarian Nordic to Report New PROSTVAC® Clinical Data at the American Society of Clinical Oncology Annual Meeting

KVISTGAARD, Denmark, May 18, 2012 - Bavarian Nordic A/S (OMX: BAVA) today announced that new interim data from an ongoing, Phase 2 randomized trial of the Company's PROSTVAC®therapeutic cancer vaccine when used in combination with Quadramet® (samarium-153 EDTMP), a commercially available skeletal-targeted radiopharmaceutical, will be presented as a poster during the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois on June 2, 2012.

Bavarian Nordic's PROSPECT, a single global, randomized, double-blind, placebo-controlled Phase 3 study of PROSTVAC® in prostate cancer patients with metastatic disease who have failed hormone therapy is also the subject of a "Trials in Progress" abstract, which is designed to provide an opportunity for members of the research community to present ongoing trials, foster collaboration, and discuss correlatives and novel trial designs.

Abstract titles and presentation times are provided below.

  • "Interim analysis of a phase 2 randomized clinical trial of Samarium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration resistant prostate cancer (mCRPC) after docetaxel", abstract number 2526, Poster Discussion Session, Developmental Therapeutics - Clinical Pharmacology and Immunotherapy from 8:00 AM to 12:00 PM CT on Saturday June 2, 2012.
  • "Prospect: A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC®", abstract number TPS4699, General Poster Session, Genitourinary Cancer from 8:00 AM to 12:00 PM CT on Sunday June 3, 2012.

Bavarian Nordic will also be hosting a PROSTVAC® update and reception on Monday, June 4, 2012 in Chicago, Illinois. The principal investigators for the PROSPECT trial, James L. Gulley, M.D., Ph.D., Director of the Clinical Trials Group at the Laboratory of Tumor Immunology and Biology at the National Cancer Institute (NCI), and Philip Kantoff M.D., Professor of Medicine at Harvard Medical School, will be joined by members of the Company's senior management team to discuss this next-generation prostate cancer vaccine. To register for this event, or for more information, please contact Mette Buhl of Bavarian Nordic via email at or by phone at +45 33 28 83 00.